CN102014955A - 含醣基广谱癌症标志物 - Google Patents

含醣基广谱癌症标志物 Download PDF

Info

Publication number
CN102014955A
CN102014955A CN200880001243XA CN200880001243A CN102014955A CN 102014955 A CN102014955 A CN 102014955A CN 200880001243X A CN200880001243X A CN 200880001243XA CN 200880001243 A CN200880001243 A CN 200880001243A CN 102014955 A CN102014955 A CN 102014955A
Authority
CN
China
Prior art keywords
antibody
sample
monoclonal antibody
igg
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880001243XA
Other languages
English (en)
Chinese (zh)
Inventor
吉祐·葛瑞格·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vancouver Biotech Ltd
Original Assignee
Vancouver Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vancouver Biotech Ltd filed Critical Vancouver Biotech Ltd
Publication of CN102014955A publication Critical patent/CN102014955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880001243XA 2007-05-14 2008-05-14 含醣基广谱癌症标志物 Pending CN102014955A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91790607P 2007-05-14 2007-05-14
US60/917,906 2007-05-14
US4402808P 2008-04-10 2008-04-10
US61/044,028 2008-04-10
PCT/CA2008/000932 WO2008138139A1 (en) 2007-05-14 2008-05-14 Carbohydrate-containing pan cancer marker

Publications (1)

Publication Number Publication Date
CN102014955A true CN102014955A (zh) 2011-04-13

Family

ID=40001646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880001243XA Pending CN102014955A (zh) 2007-05-14 2008-05-14 含醣基广谱癌症标志物

Country Status (7)

Country Link
US (2) US8143373B2 (https=)
EP (1) EP2155250B1 (https=)
JP (1) JP5683948B2 (https=)
CN (1) CN102014955A (https=)
AU (1) AU2008250953B2 (https=)
CA (1) CA2687403A1 (https=)
WO (1) WO2008138139A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102901817A (zh) * 2011-07-27 2013-01-30 北京大学 Non-B Ig单抗RP215在细胞增殖、迁移及干细胞研究中的应用
CN105353132A (zh) * 2015-11-13 2016-02-24 北京大学 non B-s IgG作为干/祖细胞标志物的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006718A1 (en) * 2010-07-14 2012-01-19 Vancouver Biotech Ltd. Carbohydrate hapten-based anti-cancer vaccines and antibody drugs
US8974786B2 (en) * 2012-06-13 2015-03-10 Vancouver Biotech Ltd. Humanized antibodies to CA215
WO2018119518A1 (en) 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
CN108484777B (zh) * 2017-03-31 2022-07-12 李吉祐 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650291A (en) * 1989-07-31 1997-07-22 The University Of British Columbia Monoclonal antibodies against an antigen associated with ovarian cervical and other tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6312924B1 (en) * 1999-03-18 2001-11-06 Zymogenetics, Inc. Murine interferon-α
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US20050222392A1 (en) * 2002-04-09 2005-10-06 Graham Carter Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
EP1677773A1 (en) * 2003-10-14 2006-07-12 Biomira, Inc. Combination therapy for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650291A (en) * 1989-07-31 1997-07-22 The University Of British Columbia Monoclonal antibodies against an antigen associated with ovarian cervical and other tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREGORY LEE,ET AL: "Recent Studies of a New Carbohydrate-Associated Pan Cancer Marker,CA215", 《JOURNAL OF CLINICAL LIGAND ASSAY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102901817A (zh) * 2011-07-27 2013-01-30 北京大学 Non-B Ig单抗RP215在细胞增殖、迁移及干细胞研究中的应用
CN105353132A (zh) * 2015-11-13 2016-02-24 北京大学 non B-s IgG作为干/祖细胞标志物的应用

Also Published As

Publication number Publication date
EP2155250A1 (en) 2010-02-24
EP2155250B1 (en) 2015-04-15
AU2008250953A1 (en) 2008-11-20
US8143373B2 (en) 2012-03-27
US20120177636A1 (en) 2012-07-12
JP5683948B2 (ja) 2015-03-11
EP2155250A4 (en) 2011-04-13
JP2010529950A (ja) 2010-09-02
AU2008250953B2 (en) 2013-10-31
US20110033445A1 (en) 2011-02-10
CA2687403A1 (en) 2008-11-20
WO2008138139A1 (en) 2008-11-20
AU2008250953A2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
Pastan et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas
von Mensdorff‐Pouilly et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n‐acetylgalactosamine (GalNAc) peptides
US8722362B2 (en) Monoclonal antibodies against HER2 antigens, and uses therefor
Palitzsch et al. A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer
Mazal et al. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer
CN102014955A (zh) 含醣基广谱癌症标志物
EP2971047A1 (en) Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
JP2849683B2 (ja) 「動物及びヒトのムチンを用い、並びに合成炭水化物−担体結合物を用いた免疫による、ヒト癌関連抗原に対するモノクローナル抗体」
US20040001789A1 (en) Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
NZ512722A (en) Use of Ep-CAM antibodies for anticancer vaccination
US5338661A (en) Monoclonal antibody specific for a human tumour-associated antigen
US4962187A (en) Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
US20020006629A1 (en) Affinity matrix bearing tumor-associated carbohydrate-or glycopeptide-based antigens and uses thereof
US9346867B2 (en) Cancer-related glycopeptide epitopes, antibodies and methods of use
Machado et al. Physicochemical and biological characterization of 1E10 anti-idiotype vaccine
CN114349864B (zh) 抗前列腺酸性磷酸酶抗体及其用途
CA1341323C (en) Method and composition for preventing growth and replication of cancer cells that express the core structure of a mucin-type glycoprotein
US20130195873A1 (en) Carbohydrate hapten-based anti-cancer vaccines and antibody drugs
LV10202B (en) Human carcinoma-associated antigen and antibody binding to the antigen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110413